Skip to main content

Share story

Infrastructure

Meta scoops up more of Nvidia's AI chip output

Meta scoops up more of Nvidia's AI chip output Image: Primary
Nvidia has entered into a multi-year strategic partnership with Meta to equip the social network's new AI data centers with its processors. Under the agreement Nvidia will supply Meta with millions of Blackwell and Rubin GPUs. Meta will integrate Nvidia Spectrum-X Ethernet switches into its Facebook Open Switching System platform. Meta will also expand its use of Nvidia Grace chips in what Nvidia described as the first large-scale Grace-only deployment. Grace CPUs are usually paired with Nvidia Blackwell GPUs. Nvidia Chief Executive Jensen Huang said in a news release that no one deploys AI at Meta's scale. Meta plans capital expenditure of 115 billion to 135 billion dollars this year mostly on data centers and the computing infrastructure they contain. Meta is keeping it all for itself.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Network World and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.